LeadingBiotech: Cancer Advance is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Tyler Jacks, Ph.D.
Director, Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology

Profile

Tyler Jacks, PhD is the Director of the Koch Institute for Integrative Cancer Research at MIT, the David H. Koch Professor of Biology, and an Investigator of the Howard Hughes Medical Institute. Over the course of his career at MIT, Dr. Jacks has pioneered the use of gene targeting technology to study cancer-associated genes and to construct models of many human cancer types, including cancers of the lung, brain, and ovary. His laboratory has made seminal contributions to the understanding of the effects of mutations of several common cancer-associated genes. This research has led to novel insights into tumor development, normal development and other cellular processes, as well as new strategies for cancer detection and treatment. Dr. Jacks has published more than 300 scientific papers.

Dr. Jacks has served on the Board of Scientific Advisors of the National Cancer Institute, is the immediate past chair of the National Cancer Advisory Board, and served as co-chair of Vice President Biden’s Cancer Moonshot’s Blue Ribbon Panel. He is an advisor to several biotechnology and pharmaceutical companies, and is a member of the Board of Directors of Amgen and Thermo Fisher Scientific. He is a founder of T2 Biosciences and Dragonfly Therapeutics, where he serves as chair of the Scientific Advisory Board.

Among many honors, Dr. Jacks is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the Fellows of the American Association of Cancer Research Academy. In 2015, he received the Killian Award, the highest honor MIT bestow upon a member of its faculty.


Agenda Sessions

  • Moderated Keynote: Advances in Cancer Research and What Lies Ahead